SRPT

Sarepta Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · sarepta.com

$22.04

Mkt Cap $2.3B

52w Low $10.42 21.4% of range 52w High $64.80

50d MA $19.54 200d MA $19.70

P/E (TTM) -3.0x

EV/EBITDA -3.8x

P/B 2.0x

Debt/Equity 0.9x

ROE -36.1%

P/FCF -7.3x

RSI (14) —

ATR (14) —

Beta 0.28

50d MA $19.54

200d MA $19.70

Avg Volume 2.8M

About

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 25, 2026	AMC	-1.03	-3.58	-247.6%	18.97	-6.2%	-8.0%	-11.7%	-14.0%	-16.3%	-15.2%	+5.3%	—
Nov 3, 2025	AMC	0.01	-0.13	-1400.0%	24.45	-37.7%	-33.7%	-23.6%	-27.9%	-27.9%	-29.4%	-10.7%	—
Aug 6, 2025	AMC	1.11	2.02	+82.0%	16.26	+12.2%	+10.5%	+12.1%	+10.3%	+15.6%	+25.5%	+15.1%	—
May 6, 2025	AMC	0.35	-3.42	-1077.1%	46.75	-14.5%	-21.5%	-21.9%	-22.4%	-22.2%	-22.6%	-16.1%	—
Feb 26, 2025	AMC	1.38	1.50	+8.7%	106.86	-5.5%	-3.6%	-0.1%	-5.3%	-3.7%	+0.8%	-34.1%	—
Nov 6, 2024	AMC	-0.06	0.62	+1139.7%	127.97	+3.5%	-5.9%	-5.0%	-7.9%	-10.7%	-12.1%	+0.2%	—
Aug 7, 2024	AMC	0.01	0.07	+1200.7%	140.06	-3.6%	-2.6%	-10.5%	-8.1%	-4.7%	-5.0%	-8.0%	—
May 1, 2024	AMC	0.10	0.73	+625.6%	130.90	+7.0%	-0.2%	+2.1%	+3.2%	+3.9%	+1.3%	-0.8%	—
Feb 28, 2024	AMC	0.01	0.47	+3084.0%	137.50	-0.6%	-7.0%	-6.4%	-9.9%	-10.7%	-12.5%	-6.6%	—
Nov 1, 2023	AMC	-1.66	-0.46	+72.3%	76.52	+3.8%	+1.6%	+1.9%	+4.7%	+8.4%	+5.4%	+10.4%	—
Aug 2, 2023	AMC	-1.89	-0.27	+85.7%	105.19	+2.7%	+2.1%	+0.1%	-2.6%	-2.0%	-1.7%	+16.5%	—
May 2, 2023	AMC	-1.46	-0.97	+33.6%	123.69	-2.6%	+1.4%	+5.2%	+5.9%	+2.5%	+1.4%	+0.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 16	HC Wainwright & Co.	Maintains	Sell → Sell	—	$21.73	$21.75	+0.1%	-2.6%	-0.8%	-1.4%	-4.8%	-5.0%
Mar 26	Citigroup	Maintains	Sell → Sell	—	$23.77	$23.15	-2.6%	-8.8%	-16.0%	-13.8%	-8.5%	-6.9%
Mar 26	Needham	Maintains	Underperform → Underperform	—	$23.77	$23.15	-2.6%	-8.8%	-16.0%	-13.8%	-8.5%	-6.9%
Mar 19	Oppenheimer	Maintains	Outperform → Outperform	—	$17.16	$16.94	-1.3%	-3.0%	-2.7%	+3.2%	+2.6%	+38.5%
Mar 13	Mizuho	Maintains	Outperform → Outperform	—	$17.04	$17.47	+2.5%	-3.8%	-2.2%	-1.2%	+0.7%	-2.3%
Mar 10	Citigroup	Maintains	Sell → Sell	—	$17.64	$17.63	-0.1%	+0.1%	-0.3%	-3.4%	-7.0%	-5.6%
Mar 2	HC Wainwright & Co.	Maintains	Sell → Sell	—	$16.76	$16.28	-2.9%	-2.6%	-5.3%	-4.0%	-3.2%	-0.3%
Feb 27	Wells Fargo	Maintains	Overweight → Overweight	—	$17.45	$17.17	-1.6%	-4.0%	-6.5%	-9.1%	-7.8%	-7.0%
Jan 27	HC Wainwright & Co.	Maintains	Sell → Sell	—	$22.80	$22.30	-2.2%	-2.8%	-6.5%	-6.8%	-10.8%	-9.1%
Jan 23	Wedbush	Maintains	Outperform → Outperform	—	$21.79	$21.89	+0.5%	-3.0%	+4.6%	+1.7%	-2.2%	-2.5%
Jan 14	HC Wainwright & Co.	Maintains	Sell → Sell	—	$21.46	$21.56	+0.5%	+6.2%	-0.7%	-1.5%	-2.0%	-0.4%
Nov 5	Wells Fargo	Maintains	Overweight → Overweight	—	$16.20	$16.59	+2.4%	+15.2%	+8.9%	+8.8%	+6.6%	+11.0%
Nov 5	Guggenheim	Maintains	Buy → Buy	—	$16.20	$16.59	+2.4%	+15.2%	+8.9%	+8.8%	+6.6%	+11.0%
Nov 5	Mizuho	Upgrade	Neutral → Outperform	—	$16.20	$16.59	+2.4%	+15.2%	+8.9%	+8.8%	+6.6%	+11.0%
Nov 5	Barclays	Maintains	Equal Weight → Equal Weight	—	$16.20	$16.59	+2.4%	+15.2%	+8.9%	+8.8%	+6.6%	+11.0%
Nov 4	Baird	Maintains	Neutral → Neutral	—	$24.45	$15.24	-37.7%	-33.7%	-23.6%	-27.9%	-27.9%	-29.4%
Oct 30	Piper Sandler	Maintains	Neutral → Neutral	—	$23.45	$23.22	-1.0%	-0.9%	+2.4%	+4.3%	-30.9%	-20.4%
Sep 22	BMO Capital	Upgrade	Market Perform → Outperform	—	$17.43	$18.50	+6.1%	+7.0%	+2.9%	+4.8%	+1.7%	+5.3%
Sep 15	Guggenheim	Maintains	Buy → Buy	—	$17.39	$17.47	+0.5%	+0.5%	+4.1%	-2.0%	+6.5%	+0.2%
Sep 9	Leerink Partners	Maintains	Market Perform → Market Perform	—	$17.60	$17.72	+0.7%	+0.2%	-2.2%	+1.8%	-1.2%	-0.7%
Aug 25	HC Wainwright & Co.	Maintains	Sell → Sell	—	$20.22	$20.27	+0.2%	-10.7%	-9.7%	-10.6%	-9.3%	-10.0%
Aug 21	BofA Securities	Maintains	Underperform → Underperform	—	$20.58	$19.37	-5.9%	-2.5%	-1.7%	-12.2%	-11.3%	-12.2%
Aug 20	BofA Securities	Maintains	Underperform → Underperform	—	$20.18	$20.17	-0.0%	+2.0%	-0.6%	+0.2%	-10.5%	-9.5%
Aug 15	Deutsche Bank	Maintains	Sell → Sell	—	$20.30	$20.43	+0.6%	+7.4%	+3.4%	-0.6%	+1.4%	-1.2%
Aug 7	Wells Fargo	Maintains	Overweight → Overweight	—	$16.26	$18.25	+12.2%	+10.5%	+12.1%	+10.3%	+15.6%	+25.5%
Aug 7	Goldman Sachs	Maintains	Neutral → Neutral	—	$16.26	$18.25	+12.2%	+10.5%	+12.1%	+10.3%	+15.6%	+25.5%
Jul 30	Barclays	Upgrade	Underweight → Equal Weight	—	$15.83	$17.68	+11.7%	+5.8%	+3.7%	+0.5%	+8.0%	+5.8%
Jul 29	Needham	Maintains	Underperform → Underperform	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	Oppenheimer	Upgrade	Perform → Outperform	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	JP Morgan	Upgrade	Underweight → Neutral	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	BMO Capital	Maintains	Market Perform → Market Perform	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	Piper Sandler	Maintains	Neutral → Neutral	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 29	Barclays	Upgrade	Underweight → Equal Weight	—	$13.86	$18.23	+31.5%	+14.2%	+20.9%	+18.5%	+14.8%	+23.4%
Jul 28	Needham	Maintains	Underperform → Underperform	—	$11.93	$11.71	-1.8%	+16.2%	+32.7%	+40.4%	+37.6%	+33.4%
Jul 27	Barclays	Downgrade	Equal Weight → Underweight	—	—	—	—	—	—	—	—	—
Jul 25	JP Morgan	Downgrade	Neutral → Underweight	—	$12.88	$11.14	-13.5%	-7.4%	+7.6%	+22.9%	+30.0%	+27.5%
Jul 25	Deutsche Bank	Maintains	Sell → Sell	—	$12.88	$11.14	-13.5%	-7.4%	+7.6%	+22.9%	+30.0%	+27.5%
Jul 24	Jefferies	Maintains	Buy → Buy	—	$13.32	$12.78	-4.1%	-3.3%	-10.4%	+4.1%	+18.8%	+25.8%
Jul 24	Wells Fargo	Maintains	Overweight → Overweight	—	$13.32	$12.78	-4.1%	-3.3%	-10.4%	+4.1%	+18.8%	+25.8%
Jul 23	BofA Securities	Downgrade	Neutral → Underperform	—	$13.62	$13.44	-1.3%	-2.2%	-5.4%	-12.4%	+1.8%	+16.2%
Jul 22	Barclays	Downgrade	Overweight → Equal Weight	—	$13.32	$12.45	-6.5%	+2.3%	+0.0%	-3.3%	-10.4%	+4.1%
Jul 22	Needham	Maintains	Underperform → Underperform	—	$13.32	$12.45	-6.5%	+2.3%	+0.0%	-3.3%	-10.4%	+4.1%
Jul 22	Piper Sandler	Maintains	Neutral → Neutral	—	$13.32	$12.45	-6.5%	+2.3%	+0.0%	-3.3%	-10.4%	+4.1%
Jul 22	BMO Capital	Maintains	Market Perform → Market Perform	—	$13.32	$12.45	-6.5%	+2.3%	+0.0%	-3.3%	-10.4%	+4.1%
Jul 21	Leerink Swann	Downgrade	Outperform → Market Perform	—	$14.08	$12.82	-8.9%	-5.4%	-3.3%	-5.4%	-8.5%	-15.3%
Jul 21	Mizuho	Downgrade	Outperform → Neutral	—	$14.08	$12.82	-8.9%	-5.4%	-3.3%	-5.4%	-8.5%	-15.3%
Jul 21	Deutsche Bank	Downgrade	Hold → Sell	—	$14.08	$12.82	-8.9%	-5.4%	-3.3%	-5.4%	-8.5%	-15.3%
Jul 21	JP Morgan	Maintains	Overweight → Overweight	—	$14.08	$12.82	-8.9%	-5.4%	-3.3%	-5.4%	-8.5%	-15.3%
Jul 21	Piper Sandler	Maintains	Neutral → Neutral	—	$14.08	$12.82	-8.9%	-5.4%	-3.3%	-5.4%	-8.5%	-15.3%

Recent Filings

8-K

Unknown — 8-K Filing

A new executive compensation package signals leadership continuity, but the $540,000 salary and 40% bonus structure indicate moderate executive costs that shouldn't meaningfully impact shareholder value.

Apr 15

8-K · 5.02 !!! Very High

Sarepta Therapeutics,, Inc. -- 8-K 5.02: Executive Change

Sarepta Therapeutics initiated a CEO search following Douglas Ingram's departure, potentially signaling leadership transition uncertainty that could impact investor confidence in the gene therapy company's strategic direction.

Feb 25

8-K

Sarepta Therapeutics,, Inc. -- 8-K Filing

Sarepta Therapeutics reported its Q4 and full-year 2025 financial results, providing investors with updated revenue, profitability, and operational metrics for the precision genetic medicine company.

Feb 25

Data updated apr 27, 2026 2:51am · Source: massive.com